Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 16 November 2017

Summit Therapeutics plc : Miscellaneous

     

Published: 08:00 CET 16-11-2017 /GlobeNewswire /Source: Summit Therapeutics plc / : SUMM /ISIN: GB00BN40HZ01

Summit Therapeutics plc : Miscellaneous

Summit Therapeutics plc

("Summit" or the "Company")

 

SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER

 

Oxford, UK, 16 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces the appointment of Panmure Gordon as joint broker with immediate effect to act alongside N+1 Singer.

 

 

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

 

Contacts

 

Summit
Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office)

 

 

Tel: +44 (0)1235 443 951

  +1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Tony Rawlinson

 

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Broker)

Aubrey Powell / Jen Boorer 

 

Tel: +44 (0)20 7496 3000

Pamure Gordon (Joint Broker)

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Tel: +44 (0)20 7886 2500

 

 

MacDougall Biomedical Communications (US)

Karen Sharma

Tel: +1 781 235 3060

ksharma@macbiocom.com

 

Consilium Strategic Communications (UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Philippa Gardner

Tel: +44 (0)20 3709 5700

summit@consilium-comms.com

 

-END-

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Summit Therapeutics plc, 85b Park Drive Milton Park, Abingdon OX14 4RY,, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.